No Simple Fix For Precipitate Problem; Hana Withdraws Zensana NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Hana also drops its SPA request for Marqibo, citing a change in FDA policy on open-label oncology trials.
You may also be interested in...
Talon May Soon Have First Marqibo Approval In Its Grasp
Biotech formerly known as Hana Biosciences submits NDA for the nano-encapsulated vincristine for use as salvage in adults with Ph- ALL.
Talon May Soon Have First Marqibo Approval In Its Grasp
Biotech formerly known as Hana Biosciences submits NDA for the nano-encapsulated vincristine for use as salvage in adults with Ph- ALL.
Hana Passes Zensana Development To Par
Deal valued at up to $50 million will allow Hana to proceed with development of oncology candidates, Hana said.